• SPX
  • $5,736.58
  • 0.42 %
  • $23.89
  • DJI
  • $41,922.14
  • 0.31 %
  • $127.53
  • N225
  • $38,474.90
  • 1.11 %
  • $421.23
  • FTSE
  • $8,158.01
  • -0.32 %
  • -$26.23
  • IXIC
  • $18,291.15
  • 0.61 %
  • $111.16
Reata Pharmaceuticals, Inc. (RETA) Stock Price, News & Analysis

Reata Pharmaceuticals, Inc. (RETA) Stock Price, News & Analysis

Currency in USD Disclaimer

NA

NA

NA

Day's range
$172.32
Day's range
$172.46
50-day range
$104.5
Day's range
$172.46
  • Country: US
  • ISIN: US75615P1030
52 wk range
$21.83
Day's range
$172.46
Notice: This company has been marked as potentially delisted and may not be actively trading.


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 3.85
  • Piotroski Score 1.00
  • Grade Neutral
  • Symbol (RETA)
  • Company Reata Pharmaceuticals, Inc.
  • Price $172.36
  • Changes Percentage (0.02%)
  • Change $0.04
  • Day Low $172.32
  • Day High $172.46
  • Year High $172.46

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/05/2023
  • Fiscal Year End N/A

  • Average Stock Price Target $46.00
  • High Stock Price Target $115.00
  • Low Stock Price Target $27.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Buy
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.60
  • Trailing P/E Ratio -66.292307692308
  • Forward P/E Ratio -66.292307692308
  • P/E Growth -66.292307692308
  • Net Income $-311,901,000

Income Statement

Quarterly

Annual

Latest News of RETA

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.